Conatumumab
As of the edition of 20 October 2026, Conatumumab is an antibody: went quiet in 2020; acts on TNFRSF10B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Antibody
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Conatumumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B | O14763 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 7 | 0 | 2 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Immunitybio | Lead sponsor of trials | 2007 to now |
| Amgen | Lead sponsor of trials | 2007 to now |
| TetraLogic Pharmaceuticals | Lead sponsor of trials | 2013 to now |